{{Rsnum
|rsid=4646437
|Gene=CYP3A4
|Chromosome=7
|position=99767460
|Orientation=minus
|GMAF=0.2713
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=CYP3A4
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 83.2 | 15.9 | 0.9
| HCB | 75.9 | 23.4 | 0.7
| JPT | 78.8 | 19.5 | 1.8
| YRI | 1.4 | 27.9 | 70.7
| ASW | 12.3 | 38.6 | 49.1
| CHB | 75.9 | 23.4 | 0.7
| CHD | 75.2 | 22.9 | 1.8
| GIH | 47.5 | 39.6 | 12.9
| LWK | 0.0 | 24.5 | 75.5
| MEX | 60.3 | 36.2 | 3.4
| MKK | 14.7 | 47.4 | 37.8
| TSI | 82.4 | 16.7 | 1.0
| HapMapRevision=28
}}
{{PMID Auto
|PMID=19801957
|Title=The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test
}}

{{PMID|17465708}} Sex-dependent genetic markers of CYP3A4 expression and activity in human liver microsomes.

{{PMID|18825162|OA=1
}} Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans.

{{PMID|18978522}} CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients.

{{PMID Auto
|PMID=23609392
|Title=Pharmacogenetic study on risperidone long-acting injection: influence of cytochrome P450 2D6 and pregnane X receptor on risperidone exposure and drug-induced side-effects.
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}